749 related articles for article (PubMed ID: 19031669)
1. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
2. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
3. Global harmonization is not all that global: divergent approaches in drug safety.
Castle GH; Kelly B
Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
[No Abstract] [Full Text] [Related]
4. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
5. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
6. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
Faden LB; Milne CP
Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
[No Abstract] [Full Text] [Related]
7. Regulatory science as culture: contested two-dimensional values at the US FDA.
Abraham J
Sci Cult (Lond); 2002 Sep; 11(3):309-35. PubMed ID: 15971364
[No Abstract] [Full Text] [Related]
8. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
9. Regulatory experts debate FDA's authority.
Young D
Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
[No Abstract] [Full Text] [Related]
10. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference.
Enzi MB
Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090
[No Abstract] [Full Text] [Related]
11. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
12. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
13. Bush tails follow-ons.
Fox J
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
[No Abstract] [Full Text] [Related]
14. Looking abroad: clinical drug trials.
Hathaway CR; Manthei JR; Haas JB; Scherer CA
Food Drug Law J; 2008; 63(3):673-81. PubMed ID: 19031667
[No Abstract] [Full Text] [Related]
15. FDA to steer nanotech.
Fox JL
Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
[No Abstract] [Full Text] [Related]
16. Harmonization in the regulation of pharmaceutical research and human rights: the need to think globally.
Dominguez-Urban I
Cornell Int Law J; 1997; 30(2):245-86. PubMed ID: 12194190
[No Abstract] [Full Text] [Related]
17. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
18. The "tone at the top": can it mitigate C-suite personal liability?
Page GV; Waring MA; Kaiser GR; Cornish K
Food Drug Law J; 2008; 63(3):723-34. PubMed ID: 19031671
[No Abstract] [Full Text] [Related]
19. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
20. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
Zierenberg O
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
